BioMedInvest AG I, LSP Life Sciences Partners and TVM Capital closed a CHF 17m series-A round for Vivendy Therapeutics Ltd., a bio-pharmaceutical company located in Basel, Switzerland. Vivendy is a pharmaceutical start-up company that is developing an enzyme replacement therapy (ERT) for Morbus Morquio (Mucopolysaccharidosis (MPS) IVA), a rare lysosomal storage disease. It was founded in 2006 as a spin-off from Inotech Biotechnologies AG.